What is a biomarker?
A biomarker is a dynamic and informational biological substance that can be objectively measured and evaluated as an indicator of a normal biological process, pathogenic processes and its progression or the pharmacologic responses to a therapeutic intervention. There are different kinds of biomarkers:
- Predictory biomarkers that are disease-associated and can indicate whether there is a threat of disease or can measure a patients’ responsiveness to treatment.
- Diagnostic biomarkers that are used for diagnosis of an existing disease and staging of disease biomarkers. These biomarkers can also be used to stratify patients by disease type and may provide significant predictive value for treatment response.
- Prognostic biomarkers that predict the future outcome of a disease in an individual and can predict overall survival rate and clinical benefit from a therapeutic intervention. These biomarkers are often used to establish inclusion criteria for a clinical trial or for defining a patient population.
- Mechanistic biomarkers that may inform and validate the mechanism(s) of action of a particular treatment
- Pharmacodynamicbiomarkers that are signatures of a certain pharmacological response to an active compound or used as biomarkers for monitoring the clinical response to an active compound or intervention.
- Surrogate end point biomarkers that may yield information on the clinical benefit/survival at earlier stages as opposed to prolonged disease-free or overall survival analysis
- Safety biomarkers that can predict at the time of patient’s enrollment her/his likelihood to suffer major toxicity from a specific therapy.
What we offer?
Svar has over 15 years’ experience of complement system assay development. Our complement system assays have been developed by our experienced scientists in close collaboration with key opinion leaders, to yield sensitive, reliable and easy-to-use products for the exploration of most aspects of the complement system.
The Svar Complement activity biomarkers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. They are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
Take advantage of our complement expertise and let us guide you on the Complement Pathway!